drugset
drugset / Trial / NCT05719805

A Study to Evaluate the Effects of Mavacamten in Healthy Participants

NCT05719805 ↗

Phase 1 Completed 84 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to evaluate the effect between two different single doses of mavamten in healthy participants.

Timeline

Start
2023-02-20
Primary completion
2023-07-25
Completion
2023-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavacamten Small molecule 15 mg —

Indications

No indication recorded.